Cancer is one of the major public health problems facing China and the world. With the aging of China's population and changes in lifestyle, the incidence of malignant tumors continues to increase. According to the latest data from the National Cancer Center based on tumor registration and follow-up monitoring, there will be 4.8247 million new cases of malignant tumors in China in 2022, and the total number of deaths will reach 2.5742 million1.

Malignant tumors are one of the major diseases that threaten the health of Chinese residents. The lifetime risk of cancer among Chinese people is 28.9%2. China has been on the road to fighting cancer.

The "Healthy China 2030" Planning Outline clearly states that by 2030, chronic disease health management will be achieved for the entire population and throughout the life cycle, and the overall 5-year cancer survival rate will increase by 15%3; the Cancer Prevention and Control Action Implementation Plan (2023-2030) proposes By 2030, the cancer prevention and treatment system will be further improved, the ability to comprehensively prevent and control risk factors, cancer screening and early diagnosis and treatment will be significantly enhanced, the level of standardized diagnosis and treatment will be steadily improved, the rising trend of cancer incidence and mortality will be curbed, and the overall cancer The 5-year survival rate reached 46.6%, and the patient's disease burden was effectively controlled4.

Driven by policy support and innovation, as well as advances in genomics and molecular biology, the development of targeted therapy and immunotherapy has been promoted, and the clinical efficacy of tumors has been further improved. Against this background, major pharmaceutical companies are actively exploring emerging therapies such as new antibody drug conjugates (ADCs), CAR-T cell therapy, and radioactive ligand therapy. Cancer treatment has entered a new era.

As a leading pharmaceutical company in the anti-tumor field, AstraZeneca’s underlying logic in developing oncology drugs is to lead a revolution in the diagnosis and treatment of tumors. Different from other pharmaceutical companies, AstraZeneca continues to create diversified innovative drugs through independent research and development, cooperative development, joint research and business expansion cooperation, and supports China's research and development to lead the world, achieving "in China, for China, and benefiting the world."

In 2024, AstraZeneca will once again deepen its presence in China and announce that Shanghai will become the fifth global strategic center, which means that China's importance in AstraZeneca's global map has once again increased. Currently, AstraZeneca's R&D pipeline in China has more than 200 projects, half of which are oncology R&D projects, and has achieved 100% global synchronized R&D. At the same time, in areas with high incidence of cancer in China, such as digestive tract tumors, let China's research and development lead AstraZeneca's global research and development, and let China become a booster for global cancer drug research and development.

According to the "2024 National Cancer Report", there will be 357,200 new cases of breast cancer in my country in 2022, ranking second among common malignant tumors in women, and the 5-year survival rate of patients with advanced breast cancer is only 20%1. In addition, there are large differences between urban and rural areas of my country and uneven regional distribution of malignant tumors. From 2012 to 2015, the 5-year survival rates of female breast cancer in urban areas and rural areas in my country were 84.9% and 72.9%, respectively1.

For more than 30 years since entering China, AstraZeneca has continuously introduced innovative breast cancer drugs into China. Based on the existing cornerstone drugs for endocrine therapy and ADC drugs, AstraZeneca has continued to accelerate the exploration of AKT inhibitors, PARP inhibitors, oral SERD, and immunotherapy. etc., to provide new treatment options for patients with different types of breast cancer.

In order to improve the efficiency of R&D and commercialization, AstraZeneca actively cooperates with innovative pharmaceutical companies. Take trastuzumab, the ADC jointly developed by AstraZeneca and Daiichi Sankyo, as an example. Its innovative breakthroughs in HER2-targeted therapy have always attracted much attention. It is worth noting that two important studies on trastuzumab have been published in the internationally renowned medical journals "New England Journal of Medicine" and "Nature Medicine" during this year's ESMO period, and are expected to once again revolutionize the treatment landscape of HER2 breast cancer.

Innovative cooperation has long been the main theme of AstraZeneca's development. It has always cooperated with all walks of life with an open mind to explore overall solutions covering the entire disease process such as prevention, screening, diagnosis, treatment, rehabilitation, and care, and promoted the establishment of a more comprehensive disease through diversified cooperation. The diagnosis and treatment system in the field of cancer brings more choices to Chinese cancer patients.

In order to help breast cancer patients achieve high-quality and long-term survival, AstraZeneca has joined hands with ecosystem partners to deepen the full-course patient management model from aspects such as accurate diagnosis of breast cancer, standardized treatment, digital intelligence management, and patient care.

AstraZeneca, as one of the supporters, has assisted the National Cancer Center in launching the construction of the Breast Cancer Center (BCCE), which will provide patients with more comprehensive, precise and personalized treatment through three important sectors: accurate diagnosis, standardized treatment and patient management. plan. BCCE has two major innovations: first, it is the first to introduce the country's first large language model (LLM) in the field of solid tumors - intelligent therapeutic doctors, and prioritizes its practical application in the field of breast cancer; second, it empowers traditional hospitals with AI technology Inter-MDT - iMDT, improves the quality and efficiency of inter-hospital consultations, and also includes quality control, providing an integrated platform for learning and smart management for primary medical service institutions to standardize treatment. As of the first half of this year, BCCE has built more than 90 hospitals.

Driven by the "troika of innovation", AstraZeneca is continuing to work with cross-border partners in various fields to build a diversified innovation ecosystem. In April this year, AstraZeneca built a breast health innovation park in Beijing. Eight companies have signed contracts to join the park in the first phase, giving full play to AstraZeneca's accumulation and advantages in the field of oncology and promoting the high-quality development of China's breast health industry.

Guided by the goals of Healthy China and cancer prevention and treatment, AstraZeneca adheres to the original intention of being "patient-centered" and works extensively with ecosystem partners to gain insight into the needs of patients throughout the disease process, provide full support from treatment to recovery, and help patients manage their aging process. The disease becomes chronic. Since 2017, AstraZeneca has supported public welfare foundations in launching public welfare projects to care for female cancer patients, such as the breast cancer digital care platform "Love Carrying" and public welfare projects "Healthy with Her" and "Born to the Best", in response to the national The spirit of health science popularization continues to innovate the form and connotation of patient science education, providing patients with full support from treatment to recovery, allowing patients to manage cancer in the long term like a chronic disease.

Recently, the 2024 CSCO Patient Education Expert Committee held a launching ceremony for the patient co-management path of the cancer patient life support plan project. The project was initiated by the Chinese Society of Rehabilitation Medicine, under the academic guidance of the CSCO Patient Education Expert Committee, and AstraZeneca is one of the supporters. , by gaining insight into the needs of breast cancer patients throughout the course of the disease, clinicians work with professional pharmacies outside the hospital to provide patients with full-course services such as standardized diagnosis and treatment, professional follow-up management and patient care, so as to improve patients' standard medication compliance, treatment confidence and treatment experience.

Xie Qiong, Vice President of AstraZeneca China and Head of Urology Oncology, Gynecology and Female Oncology Business Units, said: "AstraZeneca has been deeply involved in China for more than 30 years and has continued to innovate. We hope that by 2030, every 3 breast cancer patients will be There is one person who has benefited from AstraZeneca's drugs. In the future, we will continue to join forces with many parties to help breast cancer patients live longer and better, and help achieve the goal of 'Healthy China 2030' as soon as possible. "